Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Price Target from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.00.

Several equities analysts recently commented on the stock. Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price on the stock. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and issued a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th.

Insider Activity

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the stock in a transaction on Tuesday, November 26th. The stock was acquired at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new stake in Pyxis Oncology in the third quarter worth $1,405,000. Geode Capital Management LLC boosted its holdings in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after buying an additional 57,016 shares in the last quarter. abrdn plc grew its position in shares of Pyxis Oncology by 28.9% in the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after buying an additional 204,742 shares during the period. Millennium Management LLC increased its stake in shares of Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Finally, Barclays PLC lifted its position in Pyxis Oncology by 275.0% during the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after acquiring an additional 46,997 shares during the period. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.40 on Friday. The stock has a market capitalization of $83.26 million, a P/E ratio of -1.36 and a beta of 1.06. Pyxis Oncology has a one year low of $1.38 and a one year high of $6.85. The firm’s 50 day simple moving average is $1.62 and its two-hundred day simple moving average is $2.88.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.